Importance Several trials demonstrated the impact of novel agent-based maintenance in
newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating …

Background Despite major therapeutic advances, the rational choice of the most appropriate
first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is …

The Expression of Actin-Related Protein 2/3 Complex Subunit 5 (ARPC5) Expression in
Multiple Myeloma and its Prognostic Significance - PMC Back to Top Skip to main content NIH …

Background: Multiple myeloma (MM) is one of the most common types of hematological
malignance, and the prognosis of MM patients remains poor. Objective: To identify and …

Background Multiple myeloma is a bone marrow‐based hematological malignancy
accounting for approximately two per cent of cancers. First‐line treatment for transplant …

Choice of treatment for newly diagnosed transplant-ineligible multiple myeloma poses a
difficult task due to an ever-increasing plethora of different regimens. Attempting to clarify …

In the modern era of multiple myeloma therapeutics, proteasome inhibitor (PI) and
immunomodulatory drugs (IMiDs) have replaced chemotherapy regimens for newly …

Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple
myeloma (NDMM) include melphalan and prednisone (MP) combined with either …

Objectives To present an overview of evidence of efficacy, safety, and health-related quality
of life of lenalidomide or thalidomide for transplant-ineligible multiple myeloma. Methods A …

Multiple myeloma (MM) is one of the most common malignancies, and the clinical outcome
of patients with MM remains poor. Our objective is to screen biomarkers correlated with …